Huntsworth plc on Tuesday, May 21, announced the acquisition of Creativ-Ceuticals (CC), global pioneers in health economics and market access. With the acquisition of CC, MEDiSTRAVA (the dedicated medical division of Huntsworth) provides powerful strategic and technical capability with a global footprint including more than 340 experts across 18 offices spanning Europe, Africa, Asia, Oceania and North America.
CC supports the pharmaceutical and biotechnology industry in critical and influential decision-making to realize an asset’s value and maximize patient access to new, innovative therapies. With skill sets across value and market access, decision science and outcomes research as well as customized strategic consultancy, CC has extensive experience in evidence generation, regulatory affairs, health technology appraisals and access strategies.
“This is an exciting time for CC becoming part of Huntsworth Medical and forming an amazing group of 340 talented scientists in healthcare. Joining a professional, international top-ranking organization will allow CC to reach the next development milestone – faster, smarter and smoother. Obvious synergies will expand our offering in terms of content and scope of work. The excellent cultural match between both parties is a strong predictor of success for the benefit of our employees and clients,” said Professor Mondher Toumi, MD, MSc, PhD, President and CEO Creative-Ceuticals.
Learn more about MEDiSTRAVA here.
Click here to learn more about Creativ-Ceuticals.